- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00388427
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
May 27, 2015 updated by: Edward Chu, MD, University of Pittsburgh
Phase I Study of Cetuximab Plus Dasatinib (BMS-354825) in Advanced Solid Malignancies
This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies.
Cetuximab will be administered as an intravenous infusion weekly.
Dasatinib will be taken orally, once a day, on a continuous schedule at differing dose levels.
The primary objective of this study is to determine the toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the treatment of advanced solid tumors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, phase I study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies.
Cetuximab will be administered as an intravenous infusion on a standard dose and schedule (weekly, with the first dose at 400 mg/m2 and all subsequent weekly doses at 250 mg/m2).
Dasatinib will be administered orally on a continuous schedule at the following dose levels: 100 mg QD (once a day), 150 mg QD, and 200 mg QD.
Three to six patients will be enrolled at each dose level, and the final recommended phase II cohort will be expanded to include up to 12 additional patients.
The doses will be escalated in successive cohorts of patients.
On cycle 1, dasatinib administration will start one day prior to cetuximab administration.
One cycle will be defined as 21 days, and cycles will continue until progression of disease or intolerable toxicities occur.
Peripheral blood samples and pharmacokinetic blood samples will be taken on days 0, 1, 15, and 16 of Cycle 1 only.
In patients with accessible tumor that give consent, patients will undergo a baseline tumor biopsy and a repeat biopsy after 14-21 days of the first cycle.
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Cancer Institute - Hillman Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically confirmed solid malignancy which is recurrent or metastatic or resistant to therapy. Patients w/plan of surgery for recurrent disease post cetuximab/dasatinib are eligible providing that they receive at least 2 cycles of therapy and provide baseline and post-treatment tumor tissue for correlatives.
- Any number of prior regimens but no prior EGFR or src inhibitors.
- Age greater or equal to 18 years.
- ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to 60%).
- Life expectancy greater than 12 weeks.
Patients must have normal organ and marrow function:
- leukocytes greater than or equal to 3,000/mcL
- absolute neutrophil count greater than or equal to 1,500/mcL
- platelets greater than or equal to 100,000/mcL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of normal
- creatinine up to 1.5 x normal institutional limits
- Ability to understand and the willingness to sign a written informed Consent document.
- No concomitant medication that are CYP3A4 inducers or potent inhibitors and should not take proton pump inhibitors and H2 antagonists in the first cycle of therapy and should try to avoid taking proton pump inhibitors and H2 antagonists during rest of treatment period.
- Sexually active women of childbearing potential must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized. All WOCBP must have a negative pregnancy test prior to first receiving investigational product.
Exclusion Criteria:
- Chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Any other concurrent investigational agents.
- Patients w/ untreated brain metastases. However, patients who have stable brain disease (should be off corticosteroids) at least 4 weeks after completion of appropriate therapy are eligible.
- History of allergic reaction to monoclonal antibodies.
- Inability to swallow oral medications unless patients use a feeding tube.
- Uncontrolled angina or hypertension or any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes).
- Prolonged QTc interval on pre-entry electrocardiogram (greater than 450 msec) on both the Fridericia and Bazett's correction.
- Diagnosed or suspected congenital long QT syndrome.
- Patients currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes including: quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, erythromycins, clarithromycin, chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine.
- Any other uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements.
- History of significant bleeding disorder unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., von Willebrand's disease), diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies).
- HIV-positive patients receiving combination antiretroviral therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Advanced Solid Malignancies
|
100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
Loading dose of IV 400 mg/m^2 on Day 1 of Cycle 1; IV 250 mg/m^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the treatment of advanced solid tumors
Time Frame: Anticipated completion date December 2008
|
Anticipated completion date December 2008
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the objective response rate and overall survival in patients enrolled in the study
Time Frame: Anticipated completion date December 2008
|
Anticipated completion date December 2008
|
To evaluate tissue biomarkers that relate to EGFR and Src signaling pathways on baseline tumor tissue and to study their modulation with cetuximab/dasatinib on post-treatment tumor tissue
Time Frame: Anticipated completion date December 2008
|
Anticipated completion date December 2008
|
To measure Src in peripheral blood mononuclear cells (PBMCs) before and after therapy
Time Frame: Anticipated completion date December 2008
|
Anticipated completion date December 2008
|
To evaluate EGFR gene copy number by FISH on baseline tumor tissue
Time Frame: Anticipated completion date December 2008
|
Anticipated completion date December 2008
|
To determine pharmacokinetic parameters of dasatinib in patients with and without feeding tubes
Time Frame: Anticipated completion date December 2008
|
Anticipated completion date December 2008
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Edward Chu, MD, University of Pittsburgh
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2007
Primary Completion (Actual)
July 1, 2009
Study Completion (Actual)
February 1, 2013
Study Registration Dates
First Submitted
October 13, 2006
First Submitted That Met QC Criteria
October 13, 2006
First Posted (Estimate)
October 16, 2006
Study Record Updates
Last Update Posted (Estimate)
May 28, 2015
Last Update Submitted That Met QC Criteria
May 27, 2015
Last Verified
January 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-038
- CA180049 (Other Identifier: BMS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Solid Tumour
-
Institut Claudius RegaudMerck Sharp & Dohme LLCTerminatedMalignant Solid TumourFrance
-
SynCore Biotechnology Co., Ltd.No longer availableMalignant Solid Tumour
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMalignant Solid TumourChina
-
IpsenCompleted
-
ASLAN PharmaceuticalsCompleted
-
Boehringer IngelheimCompletedMalignant Solid TumourGermany
-
The Netherlands Cancer InstitutePfizerUnknownMalignant Solid TumourNetherlands
-
The University of Texas Health Science Center at...Merck Sharp & Dohme LLCCompleted
-
Otsuka Beijing Research InstituteCompletedMalignant Solid TumourSingapore
-
Jewish General HospitalUnknownMalignant Solid TumourCanada
Clinical Trials on Dasatinib (BMS-354825)
-
Kanto CML Study GroupEpidemiological and Clinical Research Information NetworkCompleted
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedNon-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
Kanto CML Study GroupEpidemiological and Clinical Research Information NetworkCompletedChronic Myeloid LeukemiaJapan
-
Bristol-Myers SquibbCompletedMyeloid Leukemia, Chronic, Chronic-PhaseUnited States, Australia, France, Germany, Italy, Korea, Republic of, Sweden, Taiwan, Spain, Austria, Denmark, Belgium, Canada, Ireland, Switzerland, Netherlands, Peru, United Kingdom, South Africa, Argentina, Philippines, Singapore, Russian Federation and more
-
Bristol-Myers SquibbCompletedLeukemia, Lymphoblastic, Acute, Philadelphia-Positive | Myeloid Leukemia, Chronic, Accelerated PhaseAustralia, Canada, France, Germany, Italy, Korea, Republic of, Taiwan, Thailand, United States, Spain, Austria, Denmark, Belgium, Sweden, Switzerland, Netherlands, Peru, South Africa, Philippines, Singapore, Russian Federation, Br... and more
-
Bristol-Myers SquibbCompletedProstate CancerUnited States, France, Italy
-
Bristol-Myers SquibbCompletedMyeloid Leukemia, ChronicJapan
-
M.D. Anderson Cancer CenterBristol-Myers SquibbCompletedAcute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Myelofibrosis | Leukemia, Myelomonocytic, Chronic | Hypereosinophilic Syndrome | Mastocytosis | Agnogenic Myeloid MetaplasiaUnited States
-
National Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell MyelomaUnited States